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Background. Buruli ulcer (BU) is the third most frequent 
mycobacterial disease in immunocompetent persons after 
tuberculosis and leprosy. During the last decade, eight 
weeks of antimicrobial treatment has become the standard 
of care. This treatment may be accompanied by transient 
clinical deterioration, known as paradoxical reaction. We 
investigate the incidence and the risks factors associated 
with paradoxical reaction in BU. 
Methods. The lesion size of participants was assessed by 
careful palpation and recorded by serial acetate sheet trac-
ings. For every time point, surface area was compared with 
the previous assessment. All patients received antimicro-
bial treatment for 8 weeks. Serum concentration of 25-hy-
droxyvitamin D, the primary indicator of vitamin D status, 
was determined in duplex for every sample by a radioim-
munoassay. We genotyped four polymorphisms in the 
SLC11A1 gene, previously associated with susceptibility 
to BU. For testing the association of genetic variants with 
paradoxical responses, we used a binary logistic regression 
analysis with the occurrence of a paradoxical response as 
the dependent variable. 
Results.  Paradoxical reaction occurred in 22% of the pa-
tients; the reaction was statistically significantly associated 
with trunk localization , larger lesions and genetic factors. 
The polymorphisms 3’UTR TGTG ins/ins (OR 7.19, p < .001) 
had a higher risk for developing paradoxical reaction com-
pared to ins/del or del/del polymorphisms.
Conclusions. Paradoxical reactions are common in BU. 
They are associated with trunk localization, larger lesions 
and polymorphisms in the SLC11A1 gene.





The neglected tropical disease Buruli ulcer (BU) is the third most frequent mycobacterial 
disease in immunocompetent persons after tuberculosis and leprosy [1–2]. It is caused 
by Mycobacterium ulcerans. Central to the pathogenesis is the immunosuppressant and 
necrosis inducing toxin mycolactone.
During the last decade, an antibiotic regimen of eight weeks of streptomycin and 
rifampicin was introduced [3,4]. Earlier studies reported the success of this antimicrobial 
treatment with or without surgery [5–7]. A clinical trial showed that antimicrobial treat-
ment was highly effective in patients with small lesions (cross-sectional diameter < 10 
cm), of which 96% healed without surgery [8]. 
However, during or after antibiotic treatment the BU lesions may worsen. This 
could be caused by treatment failure [9–11], but might also be due to an inflammatory 
response caused by treatment-induced recovery of the immune system, i.e. a paradoxical 
reaction. Paradoxical reactions have been described in tuberculosis and in leprosy [12,13]. 
Recent studies have recognized the existence of paradoxical reactions in BU [11,14]. In 
Australia, one in five BU patients appears to have a paradoxical reaction. Most cases oc-
curred between three and ten weeks after the start of treatment [9]. In a trial in Ghana, 
most of the cases with a paradoxical reaction (>30%) were reported at week eight after 
the beginning of antimicrobial treatment [15]. The diagnosis of paradoxical response is 
difficult; no serological markers have been identified to differentiate paradoxical reactions 
from treatment failure [15]. Paradoxical reactions can be defined clinically by worsening 
of existing lesions, or the appearance of new lesions, and histologically by the appearance 
of intense inflammation in lesions [9]. Importantly, in most areas endemic for BU, histol-
ogy is not available. In Africa, very few studies have addressed paradoxical reactions in BU 
[10,14] as well as its risk factors. In Australia, edematous lesions, use of amikacin and age 
above sixty years old were strongly associated with paradoxical reactions. In addition to 
sociodemographic and clinical features, we suggest genetic factors may influence the 
occurrence of paradoxical reactions as well. As paradoxical reactions are hypothesized 
to reflect an exaggerated immune response, genes involved in the immune response 
in infectious diseases might play a role. For BU, a polymorphism in the innate immune 
SLC11A1 gene (formerly known as NRAMP1) was previously found to be associated with 
increased susceptibility to BU [16]. Furthermore it has been shown that 1,25(OH)2D3 sup-
presses the Th1 response by down-regulating the production of pro-inflammatory cyto-
kines [17–19]. So it is possible that polymorphisms in SLC11A1 gene as well as vitamin D 
are also related to paradoxical reactions. 
In West Africa, most of the patients are below age 15 [20] and amikacin is not used 
to treat BU. As the patient demographics and treatment regimen in West-Africa are widely 
different from that of Australia, it is important to look at the risk factors for developing par-
adoxical reactions in BU in this region. In Ghana, paradoxical reactions were described in 
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patients with M. ulcerans infection with early lesions (duration < 6 months), limited to 10 
cm cross-sectional diameter [14]; large lesions that are common in west Africa were not 
included in that study. Our study focuses on the risk factors associated with paradoxical 
reactions in patients with both small and large BU lesions, during and after antimicrobial 
treatment, and examines the influence of genetic factors as well.
In West Africa, most of the patients are below age 15 [20] and amikacin is not used 
to treat BU. As the patient demographics and treatment regimen in West-Africa are widely 
different from that of Australia, it is important to look at the risk factors for developing 
paradoxical reactions in BU in this region. In Ghana, paradoxical reactions were described 
in patients with M. ulcerans infection with early lesions (duration < 6 months), limited to 10 
cm cross-sectional diameter [14]; large lesions that are common in west Africa were not 
included in that study. Our study focuses on the risk factors associated with paradoxical 
reactions in patients with both small and large BU lesions, during and after antimicrobial 
treatment, and examines the influence of genetic factors as well.
Methods 
Study population
In the present study, we included participants of two randomized clinical trials in Ghana 
and Benin. The BURULICO drug trial was a randomized controlled trial for the treatment of 
early (duration less than 6 months), limited (cross-sectional diameter, 10 cm) M. ulcerans 
infection [clintrials NCT00321178]. In this trial, patients were randomized to receive either 
8 weeks of streptomycin and rifampicin or 4 weeks of streptomycin and rifampicin fol-
lowed by 4 weeks of clarithromycin and rifampicin. The second trial is a randomized trial 
on timing of the decision on surgical intervention for BU patients treated with rifampicin 
and streptomycin [clintrials NCT01432925]. All included patients had confirmed M. ulcer-
ans infection by direct microscopy following acid-fast staining or Polymerase Chain Reac-
tion (PCR), and all received 8 weeks of antimicrobial therapy. For both trials, patients who 
are pregnant, children below five years old, patients not compliant with the antibiotic 
therapy, and patients with osteomyelitis, were excluded from the study. 
Study Design
For all patients, we recorded demographics and clinical data from the trial databases. 
In addition, we recorded the progression of the size of the lesion size by measurement 
at regular intervals. For both trials, measurements were available for the first 12 weeks 
at two-week intervals. In the BURULICO trial, lesions were measured at 14, 21, 27 weeks 
after start of treatment, and for the timing of surgical intervention trial, measurements 
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were available at 16, 20, and 28 weeks after starting treatment. For analyses, the measure-
ments at 14 and 16 weeks, at 21 and 20 weeks, and 27 and 28 weeks were considered to 
be equivalent time points.
Lesion size
Lesion measurement included the indurated area around the visible skin defect. This le-
sion measurement was drawn on an acetate sheet and the surface area was calculated for 
every individual lesion at the different time point of the follow up.
Definition of paradoxical response
We considered an increase in lesion area of more than 5% between two consecutive 
measurements as a clinically relevant change. We defined a paradoxical reaction as 
2 consecutive increases in lesion size after 1 initial decrease. We additionally performed 
all analyses (post-hoc) using a less strict definition of two consecutive increases without 
an initial decrease.
Vitamin D serum concentration
Baseline vitamin D serum concentrations were available for patients participating in the 
BURULICO trial only. Blood samples in clotted blood tubes for serum were cooled until 
centrifuged within 24 hours after collection, then stored at -20°C, and sent in frozen con-
dition from Ghana to the University Medical Center Groningen, the Netherlands, until 
processed. Serum concentration of 25-hydroxyvitamin D, the primary indicator of vitamin 
D status, was determined in duplex for every sample by a radioimmunoassay (DiaSorin, 
Stillwater, MN) [21].  The mean of these two results was used for the analyses. Currently, 
there is no international consensus on the optimal level for vitamin D [22]. In healthy 
humans, vitamin D adequacy is defined as the presence of 25(OH)D
3
 at a concentration 
of 50 –75 nmol/L, levels of 75 nmol/L or greater represent vitamin D sufficiency while 
the serum levels of 25– 50 nmol/L of circulating 25(OH)D
3
 are defined as vitamin D insuf-
ficiency [23,24].
Genetic assays
Genetic data were obtained from patients participating in the BURULICO trial. Participants 
in the trial in Benin on timing on surgical intervention, were not asked for consent to test-
ing of genetic susceptibility and could therefore not be included.  The SLC11A1 gene has 
been previously associated with susceptibility to BU [16]. We genotyped four polymor-
phisms in the SLC11A1 gene: rs59823161 (3’UTR TGTG ins/del); rs17235409 (D543 G/A); 
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rs3731865 (INT4 G/C); and a (CA)n microsatellite in  the immediate 5’ region of the gene, 
as described previously [16] . Normal genotype was designated as having a microsatellite 
length of 200 base pairs and variant genotypes, having microsatellite lengths of 202 or 
204 were pooled as “other”.
Statistics
For associations of clinical and patient characteristics with paradoxical responses, we 
used t-tests or Mann-Whitney U tests for normal and non-normal distributed continu-
ous variables and Χ2 tests for categorical variables. For testing the association of genetic 
mutations and variants with paradoxical responses, we used a binary logistic regression 
analysis with the occurrence of a paradoxical response as the dependent variable.
Ethics
The protocol was approved by the Committee on Human Research, Publication, and Eth-
ics of the Kwame Nkrumah University of Science and Technology and the Komfo Anokye 
Teaching Hospital, Kumasi (CHRPE/07/01/05), by the Ethical Review Committee of Ghana 
Health Services (GHS-ERC-01/01/06) and by the provisional national ethical review board 
of the Ministry of Health Benin, nr IRB00006860. Written and verbal informed consent 
or assent was obtained from all participants aged ≥ 12 years, and consent from parents, 
caretakers, or legal representatives of participants aged ≤ 18 years. All data were analyzed 
anonymously.
Results
Patient and clinical characteristics
A total of 241 patients were included, 150 from Ghana, and 91 from Benin; 61% were 
female. The mean (SD) age was 16.2 (13.2) years. On presentation, 45% of patients had an 
ulcer, 23% had a plaque, and 13% had a nodule; 29% had a WHO category I lesion, 55% 
a category II lesion, and 16% a category III lesion. The median (IQR) surface area of the 
lesion on presentation was 20.6 (6.6; 43.5) cm2; 49% had a lesion on the lower limb, 43% 




Paradoxical reactions, as defined by an initial decrease of the lesion followed by two con-
secutive increases occurred in 22% of cases. Most paradoxical reactions occurred between 
weeks 8 and 12 (Figure 1). When using a definition that did only require two consecutive 
increases without an initial decrease, 26% of patients had a paradoxical response, and the 
frequency distribution of the initiation week of paradoxical reaction did not differ substan-
tially. All cases that had a paradoxical reaction healed without additional treatment. 
Figure 1. Number of paradoxical reactions by weeks after starting treatment.
Associations with patient and lesion characteristics
Paradoxical reactions were significantly related to the site of lesion (p = .039 by Χ2); 44% 
of patients with a lesion on the trunk had a paradoxical response, compared to 24% of 
patients with a lesion on the upper limb, and 17% with a lesion on the lower limb.
Paradoxical reactions were also significantly related to WHO category at presenta-
tion. Ten percent of patients with a category I lesion had a paradoxical response, compared 
to 27%, and 23% of patients with a category II and category III lesion, respectively (p = .021 
by Χ2). Paradoxical reactions were not significantly related to patient age or gender. They 
were also not related to the type of lesion, duration of lesion before presentation, or white 
blood cell count at presentation (Table 1). For the participants in the BURULICO trial, 
paradoxical reactions were not related to treatment arm (8 week streptomycin vs 4 weeks 
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streptomycin followed by 4 weeks clarithromycin). The pulse and temperature at the time 
of paradoxical response did not differ from the pulse at presentation by paired samples 
t-test, and did not differ from the average pulse and temperature of those not classified as 
having a paradoxical response at the respective week. Using the less strict definition, the 
same pattern of results emerged, where paradoxical reactions were significantly related 
to the site of the lesion (p = .024 by Χ2) and WHO category at presentation (p = .009 by Χ2), 
but to none of the other variables.
Associations with vitamin D and polymorphisms in the SLC11A1 gene
Vitamin D deficiency was found in 15% of participants. The mean (SD) vitamin D level was 
66.5 (19.1) for the patients who had paradoxical reaction and 68.3 (17.1) for those who did 
not; 38% of patients with a vitamin D deficiency had a paradoxical reaction, compared to 
23% of patients without a deficiency (p = .134 by Χ2).  In the post-hoc analysis using the less 
strict definition of a paradoxical response, 33% of patients with a vitamin D deficiency had 
a paradoxical reaction, compared to 17% of patients without a deficiency (p = .082 by Χ2).
31% of patients with a 3’UTR TGTG ins/ins polymorphism had a paradoxical re-
sponse, compared to 13% of patients with a ins/del or del/del polymorphism (OR 0.14, 
95% CI: 0.05–0.44; p < 0.001). 5’(CA)
n
 microsatellite length, INT4 G/C polymorphism and 
D543N G/G polymorphism were not significantly related to paradoxical responses (Table 
1). Using the less strict definition of a paradoxical response in a post-hoc analysis, a similar 
pattern of results emerged.
Discussion
This is the first prospective study in West Africa addressing risk factors associated with 
paradoxical reaction in BU. In our sample, paradoxical reactions were common, and 
significantly associated with trunk localization, larger lesions and genetic factors. Cur-
rently, there is no standard definition of paradoxical reactions in BU. Histology, as used 
in Australia is not feasible in rural West Africa where most BU cases occur [2]. All patients 
included in this study healed without changes in therapy (no change in antibiotics, no 
corticosteroids, no surgery). This strongly supports our suggested definition and suggests 
that cases in our study represent true paradoxical reaction and not progressive disease 
secondary to antibiotic failure. 
We found a 22% incidence of paradoxical reactions (2 consecutive increases af-
ter 1 initial decrease and healing without surgery or a change in antimicrobial therapy), 
which is similar to a previous study from Australia [9].
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Table 1. Risk factors associated with paradoxical reactions. * = t-test, ǂ = Binary logistic regres-
sion, PR = paradoxical reaction, OR = Odds ratio, CI = confidence interval.




Age mean (SD) 15.2 (12.5) 16.5 (13.4) N/A 0.529*
Gender n (%)
Female 36 (24%) 117 (76%) 1




Who category n (%)
CAT 1 7 (10%) 62 (90%) 1








Site of lesion n (%)
Lower limb 20 (17%) 97 (83%) 1








Type of lesion  n (%)
Ulcerative 29 (20%) 113 (80%) 1
Non-
ulcerative




Vitamin D nmol/L  mean (SD) 66.5 (19.1) 68.3 (17.1) N/A 0.631*
3’UTR TGTG n (%)
ins/ins 22 (31%) 48 (69%) 1









G/G 25 (21%) 96 (79%) 1




A/A 0 (0%) 0 (0%) N/A
INT4 n (%)
G/G 21 (17%) 105 (83%) 1




C/C 1 (100%) 0 (0%) N/A
5’(CA)n n (%)
200/200 9 (14%) 60 (86%) 1
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In our study, most paradoxical reactions occurred between week 8 and 12–slightly 
later than the Australian study, where most paradoxical reactions occurred between week 
3 and 10 [9,11].  In the case reports from Benin paradoxical reactions occurred between 
12 and 409 days after completion of antibiotic treatment [10]. 
Mycolactone, the exotoxin produced and secreted by M. ulcerans, has been pro-
posed as the major cause of immune suppression [28–32]. Perhaps, the period between 
week 8 and 12 in which most paradoxical reactions occurred coincides with the elimina-
tion of most M. ulcerans organisms, with an arrest in the production and subsequently, 
a strong decrease in tissue concentration of mycolactone. The increase of the lesion then 
reflects an inflammatory response against the microbes—or microbial antigens of dead 
bacilli—already present in tissue which initially failed to elicit a host immune response 
[25–27,30].
We found several risk factors associated with paradoxical reactions. The incidence 
appeared to increase in larger lesions. One explanation of this may be that smaller lesions 
heal before eight weeks when most of the paradoxical reaction occurs. Another possibil-
ity is that larger lesions have a higher bacterial load than small lesions. We showed that 
lesions localized on trunk were significantly associated with paradoxical reaction, even 
when controlling for the size of the lesion. More than 4 out 10 patients (44%) with lesion 
on the trunk had paradoxical reaction compared to 24% and 17% for the upper limb and 
lower limb respectively. The increased incidence of paradoxical reactions on the trunk 
might be due to a difference in local immune responses and body temperature. 
Our study shows that paradoxical reactions were not significantly associated with 
patient age or type of lesion. This finding contrasts with Australian patients in whom asso-
ciations between paradoxical reactions and age and edema were reported [9]. This might 
be due to differences in the study populations. BU mainly affects the elderly in Australia 
[31], while in West Africa, most patients are children [32].
Paradoxical reactions were not associated with the white blood cell count or pa-
tients’ vital parameters such as the temperature and the pulse rate. We argue that an 
increase of pulse, temperature or white blood cell count is indicative of an additional 
disease or super-infection, which should be further investigated.
We also show for the first time that paradoxical reactions to M. ulcerans infection 
are associated with genetic factors. Carrying the homozygous ins/ins genotype of 3’UTR 
TGTG polymorphism in the SLC11A1 increases the risk of paradoxical reactions in BU. Ear-
lier studies have shown that genetic factors can influence the innate immune response 
to mycobacterial antigens, such as infectious disease susceptibility genes, e.g., SLC11A1, 
HLA-DR, vitamin D3 receptor, and mannose binding protein [33,34]. In BU, no associations 
were found with the 3’UTR TGTG ins/del polymorphism and developing BU [16]. However 
in tuberculosis, it was reported that participants who were heterozygous for two SLC11A1 
polymorphisms (INT4 and 3’UTR) were at highest risk of tuberculosis [34]. Perhaps, certain 
polymorphisms in the SLC11A1 gene lower the susceptibility to M. ulcerans infection by 
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developing a stronger immune response. In turn, this stronger immune response might 
increase the risk of paradoxical reactions once BU develops. It has been reported that 
genetic variation in SLC11A1 affects susceptibility to other mycobacterial diseases such as 
leprosy and tuberculosis [34,35]. However, no study addressed the genetic risk factor for 
paradoxical reaction in tuberculosis or leprosy. 
In this study, we report for the first time that paradoxical reactions are not as-
sociated with vitamin D level. Vitamin D deficiency is often found to be associated with 
susceptibility to tuberculosis [36]. Very few studies address vitamin D and paradoxical 
reactions in tuberculosis. Clearing of pathogens with anti-tuberculosis treatment and 
a delayed negative feedback on macrophage activation due to low 1,25(OH)
2
D produc-
tion from vitamin D deficiency can lead to excessive granuloma formation and an exacer-
bated inflammatory response [37]. In our sample, the means of vitamin D level in patients 
with or without paradoxical reactions were similar. 
All included patients in this study healed without any change in therapy. In ear-
lier studies corticosteroids were used to treat paradoxical reactions [9,38,39]. We would 
indeed caution for use of corticosteroids West Africa, as other infections like tuberculosis 
and strongyloidiasis may worsen. 
This study has some limitations. There are no standard definitions of paradoxical 
reactions in BU that we could use to validate our definition. Our definition is clinical and 
did not include histological aspects, which may lead to a lack of accuracy. However we 
believe that our cases accurately represent paradoxical reactions since all patients healed 
without any additional therapy. Secondly, we excluded co-infected patients with Buruli 
ulcer and HIV. This may have reduced the incidence and severity [40]. 
Paradoxical reactions are common in BU. They are associated with trunk localiza-
tion, larger lesions and certain polymorphisms in the SLC11A1 gene. There was no appar-
ent need to change therapy or add steroids.  
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